Navigation Links
Dr. John Mills and Joseph Gentile Join Board of Directors of ChanTest Corporation
Date:11/11/2009

CLEVELAND, Nov. 11 /PRNewswire/ -- ChanTest, a leading provider of cardiac safety, ion channel, and GPCR services and products for drug discovery and development, today announced that Dr. F. John Mills and Joseph Gentile have been appointed to its board of directors. Dr. Mills is presently the CEO of BioStorage Technologies, Inc., which provides management, logistics, and biological specimens and data storage services for life sciences companies. Mr. Gentile is the former Vice President and General Manager of BD Biosciences Discovery Labware, where he helped to transform the business from a commodity lab plasticware supplier to a valued partner of researchers in life science and drug discovery.

"John and Joe bring a tremendous amount of global business strategy, management, and governance expertise to ChanTest," said Dr. Arthur (Buzz) Brown, President and CEO of ChanTest. "Both individuals have been responsible for helping to re-focus businesses to accelerate growth and add value for customers and key business stakeholders - valuable perspectives that they will bring to our Board. I look forward to working closely with them to help position ChanTest for even greater success."

Dr. Mills co-founded BioStorage Technologies in 2003, which currently serves over 100 life science companies worldwide. Dr. Mills previously held roles of increasing responsibility at Covance since 1991, most recently as the Corporate Senior Vice President and President, Clinical Support Services. In addition to Covance, he has held senior management positions at Corning and Janssen Pharmaceutical. Dr. Mills received his medical degree at Cambridge University, Pembroke College, a Ph.D. from the University of Surrey, and a Diploma in Pharmaceutical Medicine from the Royal College of Physicians, Edinburgh.

Mr. Gentile joined BD Biosciences in 1996, where he served in several senior management positions of increasing responsibility. Prior to BD, Mr. Gentile also held management responsibilities at Hewlett-Packard, and engineering roles at AVCO Everett Research Lab, ELSCINT, Inc. and Advanced NMR Systems. Mr. Gentile holds a bachelor's degree in electrical engineering from Northeastern University, a master's degree in electrical engineering and an M.B.A. from Boston University, and has completed executive education programs at Harvard University and the Massachusetts Institute of Technology. He is a Director of the New England Healthcare Institute, and serves as an Advisory Board member for Vertify, Inc.

About ChanTest Corporation (www.chantest.com)

ChanTest's mission is to serve the research, drug discovery and drug development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP), cell lines, membranes and reagents; the company's library of validated ion channel cell lines is the most comprehensive, commercially available offering today. ChanTest's pre-clinical cardiac risk assessment service portfolio is the most complete offering of its kind. Since its inception in 1998, the company has tested compounds for more than 500 global pharmaceutical and biotechnology companies. ChanTest works in partnership with customers to speed the drug development process, and ultimately to help make better, safer drugs. Because of ChanTest's seminal role in the pre-clinical cardiac safety field, along with the company's uncompromising commitment to quality, ChanTest has been named the "most trusted and most used fee-for-service provider" for ion channel screening in an independent survey for the past three years. ChanTest is based in Cleveland, Ohio. For more information, e-mail info@chantest.com.

SOURCE ChanTest Corporation


'/>"/>
SOURCE ChanTest Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Saint Josephs Hospital First in Georgia to Offer Noninvasive Treatment of Brain Disorders with Leksell Gamma Knife Perfexion
2. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
3. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
4. American Board of Internal Medicine President Named to Alzheimers Study Group
5. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
6. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
9. UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials
10. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
11. Silence Therapeutics Announces Board Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 17, 2017 According to a new market ... Particle Counters), Application (Cleanroom Monitoring, Contamination Monitoring of Liquids), and End ... by MarketsandMarkets, the market is expected to reach USD 330.6 Million ... of 3.7% from 2016 to 2021. ... ...
(Date:2/17/2017)... , Feb. 17, 2017  Perrigo Company plc (NYSE, TASE: ... U.S. Food and Drug Administration for hydrocodone bitartrate and homatropine ... Hydrocodone bitartrate and homatropine methylbromide oral solution ... the symptomatic relief of cough in adults and children 6 ... months ending January 2017 were approximately $16 million.   ...
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017   ... other side effects allegedly associated with use of the ... Philadelphia Court of Common Pleas, ... a mass tort program. According to a notice posted ... scheduled to convene a meeting on March 9, 2017 ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... The Alliance Healthcare ... designed to further positively impact the health and wellness of our community in ... it our duty to seriously consider releasing our assets beyond our 5% targeted ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — ... Do manufacturers distinguish between corrective action (CA) and preventive action (PA)? , The ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... operations executives and focusing on all facets of clinical trial planning and management. ... , patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... services and financial planning assistance to families and business owners in and around ... a charity drive to help prevent all forms of domestic violence. , There ...
(Date:2/16/2017)... ... 2017 , ... The Price Agency, a Jefferson County-based firm ... the Birmingham area, is announcing an ongoing charity event to help raise support ... son, Anius. , Anius is medically complex with diagnoses consisting and not limited ...
Breaking Medicine News(10 mins):